Patents by Inventor Robert Clyde Marshall

Robert Clyde Marshall has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7317011
    Abstract: Disclosed herein are methods of treating an individual suffering from peripheral neuropathy. The methods generally include administration of a therapeutic amount of optically pure (S,S) reboxetine, or a pharmaceutically acceptable salt thereof. Embodiments of these methods can diminish adverse side effects.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: January 8, 2008
    Assignee: Pharmacia & Upjohn
    Inventors: Erik H. F. Wong, Saeeduddin Ahmed, Robert Clyde Marshall, Robert McArthur, Duncan P. Taylor
  • Publication number: 20040147614
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: January 16, 2004
    Publication date: July 29, 2004
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Erik H.F. Wong, Saeeduddin Ahmed, Robert Clyde Marshall, Robert McArthur, Duncan P. Taylor
  • Publication number: 20040058925
    Abstract: Methods and compositions for treating humans suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or a condition where inhibiting reuptake of norepinephrine is a benefit are disclosed. The compositions comprise a compound having a pharmacological selectivity of serotonin (Ki)/norepinephrine (Ki) of at least about 5000. Examples of such compounds include reboxetine, and more preferably optically pure (S,S) enantiomer of reboxetine. The methods generally include administration of a therapeutic amount of such compositions. Also disclosed are preparations of a medicament from the composition, and uses of the composition in a manufacture of the medicament to treat a human suffering from, or preventing a human from suffering, a physiological or psychiatric disease, disorder, or condition.
    Type: Application
    Filed: September 24, 2003
    Publication date: March 25, 2004
    Applicant: PHARMACIA & UPJOHN COMPANY
    Inventors: Erik H.F. Wong, Saeeduddin Ahmed, Robert Clyde Marshall, Robert McArthur, Duncan P. Taylor
  • Publication number: 20030212085
    Abstract: The present invention relates to the treatment of neuromuscular disorders and, more specifically, to the use of apomorphine, bromocriptine, pergolide, ropinirole, octahydropyrazolo[3,4-g]quinolines, and trans-(±)-substituted-5,5a,6,7,8,9-,9a,10-octahydropyrimido[4,5g]quinolines, and their pharmaceutically acceptable salts to treat, or to prepare a medicament for treating, symptoms of fibromyalgia syndrome and chronic fatigue syndrome.
    Type: Application
    Filed: October 18, 2002
    Publication date: November 13, 2003
    Inventors: Robert B. McCall, Robert Clyde Marshall
  • Publication number: 20030191149
    Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds, substituted phenylazacycloalkane-type compounds, or cabergoline-type compounds, or a salt of any said compound.
    Type: Application
    Filed: March 7, 2003
    Publication date: October 9, 2003
    Inventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
  • Patent number: 6555548
    Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of cabergoline-type compounds or a salt of said compound.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: April 29, 2003
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
  • Publication number: 20020143010
    Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds, substituted phenylazacycloalkane-type compounds, or cabergoline-type compounds, or a salt of any said compound.
    Type: Application
    Filed: May 30, 2002
    Publication date: October 3, 2002
    Inventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
  • Patent number: 6448258
    Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds or a salt of any said compound.
    Type: Grant
    Filed: April 17, 2001
    Date of Patent: September 10, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
  • Patent number: 6410579
    Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Grant
    Filed: February 14, 2001
    Date of Patent: June 25, 2002
    Assignee: Pharmacia & Upjohn Company
    Inventors: Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander
  • Publication number: 20020004510
    Abstract: The present invention provides for methods for the treatment of fibromyalgia syndrome or chronic fatigue syndrome by the administration of heterocyclic amine-type compounds, substituted phenylazacycloalkane-type compounds, or cabergoline-type compounds, or a salt of any said compound.
    Type: Application
    Filed: April 17, 2001
    Publication date: January 10, 2002
    Inventors: Robert B. McCall, Robert Clyde Marshall, David W. Robertson, Thomas M. Ashley
  • Publication number: 20010041727
    Abstract: This patent application describes the treatment addictive disorders, psychoactive substance use disorders, intoxication disorders, inhalation disorders, alcohol addiction, tobacco addiction and or nicotine addiction comprising administering a therapeutically effective, nontoxic dose of pramipexole and derivatives and or pharmaceutically acceptable salts thereof to a patient.
    Type: Application
    Filed: February 14, 2001
    Publication date: November 15, 2001
    Inventors: Robert Clyde Marshall, Erik Ho Fong Wong, Philip F. Von Voigtlander